Shots:

• The US FDA has approved IND application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) for the treatment of retinal vascular diseases
• The P-I study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with neovascular AMD in the US
• Additionally, AffaMed signed a license agreement with AskGene for the exclusive rights to develop, manufacture and commercialize AM712 in ex-Asia plus Japan territories globally

 Ref: PR Newswire | Image: LinkedIn